Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | ANPEP | P15144 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30181026 | 1.00 | MEN1 (0.38) | MEN1GAAKMT2AHTR2AANPEP | |
| SCHEMBL17343612 | 1.00 | MEN1 (0.38) | MEN1GAAKMT2AHTR2AANPEP | |
| SCHEMBL680550 | 1.00 | MEN1 (0.38) | MEN1GAAKMT2AHTR2AANPEP | |
| SCHEMBL30272955 | 0.96 | MEN1 (0.35) | MEN1GAAKMT2AHTR2AANPEP | |
| SCHEMBL30272956 | 0.76 | CYP1A2 (0.38) | MEN1KMT2A | |
| SCHEMBL5111850 | 0.75 | MEN1 (0.33) | MEN1GAAKMT2AHTR2A | |
| SCHEMBL30424597 | 0.74 | HTR2A (0.38) | MEN1GAAKMT2AHTR2AANPEP | |
| SCHEMBL8531996 | 0.74 | MAOA (0.38) | MEN1GAAKMT2AHTR2A | |
| SCHEMBL24475199 | 0.73 | MEN1 (0.33) | MEN1GAAKMT2AHTR2A | |
| SCHEMBL6237164 | 0.73 | MEN1 (0.33) | MEN1GAAKMT2AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116396189-B | Preparation method of (S) - (+) -1-indanyl isocyanate | 无锡科华生物科技有限公司 | 2024-11-05 | — | — | CN | claimed |
| CN-116396189-A | Preparation method of (S) - (+) -1-indanyl isocyanate | 无锡科华生物科技有限公司 | 2023-07-07 | — | — | CN | claimed |
| CN-122094834-A | Resin composition for three-dimensional printing | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4734985-A1 | PREVENTION, INHIBITION OR TREATMENT OF CONDITIONS OR DISORDERS MEDIATED BY UROCANATE REDUCTASE | IMPLEXION PHARMA AB (SE) | 2026-05-06 | — | — | EP | disclosed |
| US-12616193-B2 | 5-(1H-indol-3-yl)-oxazole, -oxadiazole and -furan derivatives as enhancers of sperm motility | SPERMATECH AS (NO) | 2026-05-05 | — | — | US | disclosed |
| US-12472168-B2 | Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of a disease involving gram-positive bacteria | QURETECH BIO AB (SE) | 2025-11-18 | — | — | US | disclosed |
| CN-119751905-A | Bio-based hyperbranched epoxy resin-bisphenol A type epoxy resin composite resin containing hexahydro-s-triazine structure and preparation method thereof | 中南民族大学 | 2025-04-04 | — | — | CN | disclosed |
| WO-2025003469-A1 | PREVENTION, INHIBITION OR TREATMENT OF CONDITIONS OR DISORDERS MEDIATED BY UROCANATE REDUCTASE | IMPLEXION PHARMA AB (SE) | 2025-01-02 | — | — | WO | disclosed |
| CN-116396189-B | Preparation method of (S) - (+) -1-indanyl isocyanate | 无锡科华生物科技有限公司 | 2024-11-05 | — | — | CN | disclosed |
| CN-116396189-B | Preparation method of (S) - (+) -1-indanyl isocyanate | 无锡科华生物科技有限公司 | 2024-11-05 | — | — | CN | disclosed |
| EP-4448525-A1 | PYRIMIDINE-ANNULATED TRIAZOLE DERIVATIVES AND THEIR USE IN PLATELET AGGREGATION INHIBITION | Beijing Honghui Meditech Co., Ltd. (CN) | 2024-10-23 | — | — | EP | disclosed |
| US-7582629-B2 | Derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2009-09-01 | — | — | US | disclosed |
| CN-101511839-A | Fungicidal azolopyrimidines, methods for the production thereof, use thereof for controlling harmful fungi, and substances containing the same | BASF SE (DE) | 2009-08-19 | — | — | CN | disclosed |
| US-20090029945-A2 | Non-Anilinic Derivatives of Isothiazol-3(2H)-Thione 1,1-Dioxides As Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| US-20090005353-A1 | Non-Anilinic Derivatives of Isothiazol-3(2H)-one 1,1-Dioxides as Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | disclosed |
| US-20080319017-A2 | Non-Anilinic Derivatives of Isothiazol-3(2H)-Thione 1,1-Dioxides As Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080255122-A1 | Derivatives of Isothiazol-3(2H)-One 1,1-Dioxides as Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| US-20080139616-A1 | Atherosclerosis; inflammatory diseases, Alzheimer's disease, dyslipidemia, metabolic syndrome; 2-isopropyl-5-phenyl-4-[(4-phenylbutyl)amino]isothiazole-3(2H)-thione 1,1-dioxide for example | ASTRAZENECA AB (SE) | 2008-06-12 | — | — | US | disclosed |
| US-20080125396-A1 | Derivatives of Isothiazol-3(2H)-Thione 1,1-Dioxides as Liver X Receptor Modulators | ATRAZENECA AB (SE) | 2008-05-29 | — | — | US | disclosed |
| CN-1809529-A | Pharmaceutically acceptable salts of carboxylic acid derivatives | ASTRAZENECA AB (SE) | 2006-07-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125396-A1 | Derivatives of Isothiazol-3(2H)-Thione 1,1-Dioxides as Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | MEN1 4391/4885GAA 3174/4885KMT2A 3218/4885 |
| US-20090005353-A1 | Non-Anilinic Derivatives of Isothiazol-3(2H)-one 1,1-Dioxides as Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | MEN1 4332/4885GAA 2135/4885KMT2A 2880/4885 |
| US-12616193-B2 | 5-(1H-indol-3-yl)-oxazole, -oxadiazole and -furan derivatives as enhancers of sperm motility | NR5A1, CATSPER1, HCN3 | MEN1 4620/4885GAA 4816/4885KMT2A 4007/4885 |
| US-20080319017-A2 | Non-Anilinic Derivatives of Isothiazol-3(2H)-Thione 1,1-Dioxides As Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | MEN1 4395/4885GAA 2805/4885KMT2A 3100/4885 |
| US-20080139616-A1 | Atherosclerosis; inflammatory diseases, Alzheimer's disease, dyslipidemia, metabolic syndrome; 2-isopropyl-5-phenyl-4-[(4-phenylbutyl)amino]isothiazole-3(2H)-thione 1,1-dioxide for example | NR1H2, NR1H3, SREBF1 | MEN1 4650/4885GAA 2556/4885KMT2A 3177/4885 |
| US-12472168-B2 | Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of a disease involving gram-positive bacteria | NOD2, TLR4, TLR5 | MEN1 1068/4885GAA 251/4885KMT2A 3896/4885 |
| US-20090029945-A2 | Non-Anilinic Derivatives of Isothiazol-3(2H)-Thione 1,1-Dioxides As Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | MEN1 4395/4885GAA 2805/4885KMT2A 3100/4885 |
| US-20080255122-A1 | Derivatives of Isothiazol-3(2H)-One 1,1-Dioxides as Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | MEN1 4112/4885GAA 2454/4885KMT2A 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.